ILMN Illumina, Inc.
Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
Company profile
Ticker
ILMN
Exchange
Website
CEO
Francis A. deSouza
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
Avantor • Waters • Bio-Rad Laboratories • Bruker • Agilent • Perkinelmer • Coherent • Mettler-Toledo International • Fluidigm • Harvard Bioscience ...
Former names
Illumina Inc
SEC CIK
Corporate docs
IRS number
330804655
ILMN stock data
()
Calendar
25 Oct 19
14 Dec 19
29 Dec 19
News
Company financial data Financial data
| Quarter (USD) | Sep 19 | Jun 19 | Mar 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | 907M | 838M | 846M | 867M | |
| Net income | 234M | 296M | 233M | 210M | |
| Diluted EPS | 1.58 | 1.99 | 1.57 | 1.41 | |
| Net profit margin | 25.80% | 35.32% | 27.54% | 24.22% | |
| Operating income | 308M | 205M | 204M | 197M | |
| Net change in cash | -128M | -327M | 1.13B | -202M | |
| Cash on hand | 1.82B | 1.94B | 2.27B | 1.14B | |
| Cost of revenue | 259M | 265M | 262M | 277M |
Financial data from Illumina earnings reports
Financial report summary
?Competition
Thermo Fisher Scientific • BGI • Ceres • Roche Holding • Solexa • Luminex • Biocept • Agilent • Third Wave • CareDxManagement Discussion
- To enhance comparability, the following table sets forth unaudited condensed consolidated statement of operations data for the specified reporting periods, stated as a percentage of total revenue.
- Our fiscal year is the 52 or 53 weeks ending the Sunday closest to December 31, with quarters of 13 or 14 weeks ending the Sunday closest to March 31, June 30, September 30, and December 31. The three and nine month periods ended September 29, 2019 and September 30, 2018 were both 13 and 26 weeks, respectively.
- Service and other revenue primarily consists of revenue generated from genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Total revenue relates primarily to Core Illumina for all periods presented.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
demand, extend, extended, single, slight, upfront
Removed:
abroad, avoided, commitment, discounted, field, force, identification, specific, supply
Financial reports
10-Q
2019 Q3
Quarterly report
25 Oct 19
10-Q
2019 Q2
Quarterly report
31 Jul 19
10-Q
2019 Q1
Quarterly report
26 Apr 19
10-K
2018 FY
Annual report
12 Feb 19
10-Q
2018 Q3
Quarterly report
23 Oct 18
10-Q
2018 Q2
Quarterly report
31 Jul 18
10-Q
2018 Q1
Quarterly report
25 Apr 18
10-K
2017 FY
Annual report
13 Feb 18
10-Q
2017 Q3
Quarterly report
25 Oct 17
10-Q
2017 Q2
Quarterly report
3 Aug 17
Current reports
8-K
Departure of Directors or Certain Officers
29 Nov 19
8-K
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2019
24 Oct 19
8-K
Entry into a Material Definitive Agreement
26 Sep 19
8-K
Departure of Directors or Certain Officers
29 Aug 19
8-K
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2019
29 Jul 19
8-K
Illumina Reports Preliminary Revenue for Second Quarter of Fiscal Year 2019
11 Jul 19
8-K
Other Events
18 Jun 19
8-K
Submission of Matters to a Vote of Security Holders
3 Jun 19
8-K
Illumina Reports Financial Results for First Quarter of Fiscal Year 2019
25 Apr 19
8-K
Illumina Names Susan E. Siegel to its Board of Directors
6 Feb 19
Registration and prospectus
S-8
Registration of securities for employees
7 Aug 15
S-8
Registration of securities for employees
2 Aug 13
S-8
Registration of securities for employees
19 Apr 13
SC TO-T/A
Third party tender offer statement (amended)
23 Apr 12
SC 14D9/A
Tender offer solicitation (amended)
18 Apr 12
SC TO-T/A
Third party tender offer statement (amended)
18 Apr 12
SC TO-T/A
Third party tender offer statement (amended)
12 Apr 12
SC TO-T/A
Third party tender offer statement (amended)
11 Apr 12
SC 14D9/A
Tender offer solicitation (amended)
10 Apr 12
SC 14D9/A
Tender offer solicitation (amended)
9 Apr 12
Proxies
DEFA14A
Additional proxy soliciting materials
24 May 19
DEFA14A
Additional proxy soliciting materials
16 Apr 19
DEF 14A
Definitive proxy
16 Apr 19
PRE 14A
Preliminary proxy
25 Mar 19
DFAN14A
Additional proxy materials by non-management
5 Nov 18
DFAN14A
Additional proxy materials by non-management
2 Nov 18
DEF 14A
Definitive proxy
6 Apr 18
DEFA14A
Additional proxy soliciting materials
6 Apr 18
DEF 14A
Definitive proxy
14 Apr 17
DEFA14A
Additional proxy soliciting materials
14 Apr 17
Other
SD
Conflict minerals disclosure
14 May 19
SD
Conflict minerals disclosure
30 May 18
CT ORDER
Confidential treatment order
9 Mar 18
SD
Conflict minerals disclosure
5 Jun 17
NO ACT
No action letter
25 Jan 17
SD
Conflict minerals disclosure
25 May 16
NO ACT
No action letter
18 Mar 16
CT ORDER
Confidential treatment order
24 Aug 15
SD
Conflict minerals disclosure
29 May 15
NO ACT
No action letter
17 Feb 15
Ownership
SC 13G
Twist Bioscience Corp
3 Apr 19
SC 13G/A
Illumina Inc
14 Feb 19
SC 13G/A
Illumina Inc
14 Feb 19
SC 13G/A
Illumina Inc
12 Feb 19
SC 13G/A
Illumina Inc
11 Feb 19
SC 13G/A
Illumina Inc
8 Feb 19
SC 13G/A
Illumina Inc
14 Feb 18
SC 13G/A
Illumina Inc
14 Feb 18
SC 13G/A
Illumina Inc
9 Feb 18
SC 13G/A
Illumina Inc
29 Jan 18
Patents
APP
Utility
Compositions and Methods for Single Molecular Placement on a Substrate
12 Dec 19
Provided herein are methods and compositions for placing single target molecules on a patterned substrate.
APP
Utility
Compositions, Systems, and Methods for Detecting Events Using Tethers Anchored to or Adjacent to Nanopores
12 Dec 19
Compositions, systems, and methods for detecting events are provided.
APP
Utility
Conformal Probes and Methods for Sequencing Nucleic Acids
12 Dec 19
This disclosure provides a method of determining a sequence of nucleotides for a nucleic acid template.
APP
Utility
Pressure and Leak Testing Methods
12 Dec 19
An analysis system includes a fluidic system includes a number of components that are interconnected to form a fluidic system having a plurality of flow paths.
APP
Utility
Integrated Consumer Genomic Services
12 Dec 19
The present invention provides a novel approach for consumer-driven interaction with sequencing data or genomic information.